High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

被引：33

作者：

Karuturi, Meghan ^{[1
]}

Hosing, Chitra ^{[1
]}

Fanale, Michelle ^{[2
]}

Medeiros, L. Jeffrey ^{[3
]}

Alousi, Amin M. ^{[1
]}

de Lima, Marcos J. ^{[1
]}

Qazilbash, Muzaffar H. ^{[1
]}

Kebriaei, Partow ^{[1
]}

Younes, Anas ^{[2
]}

Khouri, Issa ^{[1
]}

Andersson, Borje S. ^{[1
]}

Champlin, Richard ^{[1
]}

Anderlini, Paolo ^{[1
]}

Popat, Uday ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2013年 / 19卷 / 06期

关键词：

Hodgkin Lymphoma; Autologous stem cell transplantation; Nodular lymphocyte predominant Hodgkin lymphoma; Relapse; Chemosensitive; STUDY-GROUP GHSG; LONG-TERM; MARROW-TRANSPLANTATION; RITUXIMAB; PHASE-2; DISEASE; TRIAL;

D O I：

10.1016/j.bbmt.2013.03.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL. (C) 2013 American Society for Blood and Marrow Transplantation.

引用

页码：991 / 994

页数：4

共 50 条

[21] How I treat nodular lymphocyte-predominant Hodgkin lymphoma
Eichenauer, Dennis A.
Engert, Andreas
BLOOD, 2020, 136 (26) : 2987 - 2993
[22] Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma
Borchmann, Sven
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2022, (01) : 717 - 722
[23] Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion
Sidda, Adarsh
Naleid, Nikolas Kristopher
Manu, Gurusidda
Graffeo, Vincent
Jamil, Muhammad Omer
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2022, 10
[24] Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival
Alonso, Clayton
Dutta, Sunil W.
Mitra, Nandita
Landsburg, Daniel J.
Zaorsky, Nicholas G.
Grover, Surbhi
Peterson, Jennifer
Trifiletti, Daniel M.
CANCER MEDICINE, 2018, 7 (04): : 1118 - 1126
[25] Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Advani, Ranjana H.
Horning, Sandra J.
Hoppe, Richard T.
Daadi, Sarah
Allen, John
Natkunam, Yasodha
Bartlett, Nancy L.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (09) : 912 - +
[26] High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma
Kwonoh Park
Dok Hyun Yoon
Shin Kim
Chan-Sik Park
Jooryung Huh
Sang-Wook Lee
Cheolwon Suh
International Journal of Hematology, 2013, 97 : 256 - 262
[27] Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment
Eichenauer, Dennis A.
Hartmann, Sylvia
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (08) : 607 - 615
[28] Nodular Lymphocyte Predominant Hodgkin Lymphoma
Lee, Alfred Ian
LaCasce, Ann S.
ONCOLOGIST, 2009, 14 (07) : 739 - 751
[29] Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma
Binkley, Michael S.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (03) : 310 - 312
[30] Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
Al-Mansour, Mubarak
Connors, Joseph M.
Gascoyne, Randy D.
Skinnider, Brian
Savage, Kerry J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) : 793 - 799

← 1 2 3 4 5 →